Last reviewed · How we verify
NCT06056115
Efficacy and Safety of Tislelizumab for Lung Adenocarcinoma With Asymptomatic Brain Metastatic
NA trial testing Tislelizumab,Platinum in Lung Adenocarcinoma in 20 participants. Currently enrolling.
12 April 2025
Quick facts
| Lead sponsor | Hebei Medical University Fourth Hospital |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 20 |
| Start date | 1 May 2023 |
| Primary completion | 12 April 2025 |
| Estimated completion | 12 December 2026 |
| Sites | 1 location across China |
Drugs / interventions tested
- Tislelizumab,Platinum — full drug profile →
Conditions studied
- Lung Adenocarcinoma — all drugs for Lung Adenocarcinoma →
Sponsor
Hebei Medical University Fourth Hospital
Who can join
Adults 18 to 75, any sex, with Lung Adenocarcinoma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Brain metastasis of lung cancer is one of the most important metastasis pathways in patients with life-threatening diseases. This study explore the efficacy and safety of Tislelizumab combining with platinum-containing drug chemotherapy in the first-line treatment of Lung Adenocarcinoma With Asymptomatic Brain Metastatic. Meanwhile, Related biomarkers were explored to provide theoretical basis for efficacy evaluation and resistance mechanism.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06056115
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Lung Adenocarcinoma
Currently open trials in the same condition.
- NCT07481786 — Bevacizumab Plus FSRT Versus Hippocampus-Avoidant WBRT in Lung Adenocarcinoma With Extensive Brain Metastases · Phase 3 · recruiting
- NCT07219251 — Engagement of Veterans With Lung Cancer · NA · recruiting
- NCT07235280 — Testing the Safety of Dapagliflozin Prior to Surgery for the Treatment of Patients With Stage IA Lung Adenocarcinoma · EARLY_PHASE1 · recruiting
- NCT07161713 — SBU-RESET: RElaxation, Stress Reduction and Epigenetics Trial in Cancer Survivors · NA · recruiting
- NCT07479095 — Low-glucose/High-fat Intake Dietary Regimen as a Tool for Empowering Diagnostic Accuracy of 2-[18F]FDG PET/CT in Lepidic · NA · recruiting
Other Hebei Medical University Fourth Hospital trials
Trials by the same sponsor.
- NCT05522491 — Olaparib in the Treatment of BRCA1/2 Unmutated and BRCA1 Promoter Methylated Recurrent and Metastatic Triple-negative Br · Phase 2 · not yet recruiting
- NCT07448077 — Short-course Radiotherapy in TNT Combined With Enlonstobart for pMMR LARC · Phase 2 · not yet recruiting
- NCT07410611 — ctDNA Monitoring Guides the Treatment of NSCLC With Befotertinib Combined With Radiotherapy · Phase 2 · not yet recruiting
- NCT07131007 — Construction and Evaluation of Tumor Immunotherapy and Organ Damage Early Warning System Based on Multi-omics · recruiting
- NCT07492394 — Dalpiciclib With or Without Entinostat and Letrozole in HR+/HER2- Early Breast Cancer · Phase 2 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06056115 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Hebei Medical University Fourth Hospital
- Last refreshed: 28 September 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06056115.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing